FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891364583> ?p ?o ?g. }

• W2891364583 endingPage "1523" @default.
• W2891364583 startingPage "1516" @default.
• W2891364583 abstract "Objectives IKZF1 and IKZF3 ( encoding transcription factors Ikaros and Aiolos) are susceptibility loci for systemic lupus erythematosus (SLE). The pharmacology of iberdomide (CC-220), a cereblon ( CRBN ) modulator targeting Ikaros and Aiolos, was studied in SLE patient cells and in a phase 1 healthy volunteer study. Methods CRBN , IKZF1 and IKZF3 gene expression was measured in peripheral blood mononuclear cells (PBMC) from patients with SLE and healthy volunteers. Ikaros and Aiolos protein levels were measured by Western blot and flow cytometry. Anti-dsDNA and anti-phospholipid autoantibodies were measured in SLE PBMC cultures treated for 7 days with iberdomide. Fifty-six healthy volunteers were randomised to a single dose of iberdomide (0.03–6 mg, n=6 across seven cohorts) or placebo (n=2/cohort). CD19+ B cells, CD3+ T cells and intracellular Aiolos were measured by flow cytometry. Interleukin (IL)-2 and IL-1β production was stimulated with anti-CD3 and lipopolysaccharide, respectively, in an ex vivo whole blood assay. Results SLE patient PBMCs expressed significantly higher CRBN (1.5-fold), IKZF1 (2.1-fold) and IKZF3 (4.1-fold) mRNA levels compared with healthy volunteers. Iberdomide significantly reduced Ikaros and Aiolos protein levels in B cells, T cells and monocytes. In SLE PBMC cultures, iberdomide inhibited anti-dsDNA and anti-phospholipid autoantibody production (IC 50 ≈10 nM). Single doses of iberdomide (0.3–6 mg) in healthy volunteers decreased intracellular Aiolos (minimum mean per cent of baseline: ≈12%–28% (B cells); ≈0%–33% (T cells)), decreased absolute CD19+ B cells, increased IL-2 and decreased IL-1β production ex vivo. Conclusions These findings demonstrate pharmacodynamic activity of iberdomide and support its further clinical development for the treatment of SLE. Trial registration number NCT01733875 ; Results." @default.
• W2891364583 created "2018-09-27" @default.
• W2891364583 creator A5010267857 @default.
• W2891364583 creator A5017572254 @default.
• W2891364583 creator A5028098177 @default.
• W2891364583 creator A5034621627 @default.
• W2891364583 creator A5042912939 @default.
• W2891364583 creator A5044095153 @default.
• W2891364583 creator A5061079851 @default.
• W2891364583 creator A5072971421 @default.
• W2891364583 creator A5078233258 @default.
• W2891364583 creator A5091232638 @default.
• W2891364583 date "2018-06-26" @default.
• W2891364583 modified "2023-10-15" @default.
• W2891364583 title "Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus" @default.
• W2891364583 cites W1624447595 @default.
• W2891364583 cites W1879002358 @default.
• W2891364583 cites W1971833707 @default.
• W2891364583 cites W1973999018 @default.
• W2891364583 cites W1997952190 @default.
• W2891364583 cites W2021740276 @default.
• W2891364583 cites W2028622220 @default.
• W2891364583 cites W2029255228 @default.
• W2891364583 cites W2031580483 @default.
• W2891364583 cites W2036209857 @default.
• W2891364583 cites W2051569082 @default.
• W2891364583 cites W2052360985 @default.
• W2891364583 cites W2066713758 @default.
• W2891364583 cites W2068412287 @default.
• W2891364583 cites W2084778320 @default.
• W2891364583 cites W2115859409 @default.
• W2891364583 cites W2125477622 @default.
• W2891364583 cites W2135199713 @default.
• W2891364583 cites W2148717156 @default.
• W2891364583 cites W2170293791 @default.
• W2891364583 cites W2606131188 @default.
• W2891364583 cites W2752652435 @default.
• W2891364583 cites W4249994868 @default.
• W2891364583 doi "https://doi.org/10.1136/annrheumdis-2017-212916" @default.
• W2891364583 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6161670" @default.
• W2891364583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29945920" @default.
• W2891364583 hasPublicationYear "2018" @default.
• W2891364583 type Work @default.
• W2891364583 sameAs 2891364583 @default.
• W2891364583 citedByCount "52" @default.
• W2891364583 countsByYear W28913645832018 @default.
• W2891364583 countsByYear W28913645832019 @default.
• W2891364583 countsByYear W28913645832020 @default.
• W2891364583 countsByYear W28913645832021 @default.
• W2891364583 countsByYear W28913645832022 @default.
• W2891364583 countsByYear W28913645832023 @default.
• W2891364583 crossrefType "journal-article" @default.
• W2891364583 hasAuthorship W2891364583A5010267857 @default.
• W2891364583 hasAuthorship W2891364583A5017572254 @default.
• W2891364583 hasAuthorship W2891364583A5028098177 @default.
• W2891364583 hasAuthorship W2891364583A5034621627 @default.
• W2891364583 hasAuthorship W2891364583A5042912939 @default.
• W2891364583 hasAuthorship W2891364583A5044095153 @default.
• W2891364583 hasAuthorship W2891364583A5061079851 @default.
• W2891364583 hasAuthorship W2891364583A5072971421 @default.
• W2891364583 hasAuthorship W2891364583A5078233258 @default.
• W2891364583 hasAuthorship W2891364583A5091232638 @default.
• W2891364583 hasBestOaLocation W28913645831 @default.
• W2891364583 hasConcept C126322002 @default.
• W2891364583 hasConcept C137061746 @default.
• W2891364583 hasConcept C167672396 @default.
• W2891364583 hasConcept C170493617 @default.
• W2891364583 hasConcept C202751555 @default.
• W2891364583 hasConcept C203014093 @default.
• W2891364583 hasConcept C2776090121 @default.
• W2891364583 hasConcept C2778957590 @default.
• W2891364583 hasConcept C2908885563 @default.
• W2891364583 hasConcept C49802076 @default.
• W2891364583 hasConcept C553184892 @default.
• W2891364583 hasConcept C55493867 @default.
• W2891364583 hasConcept C71924100 @default.
• W2891364583 hasConcept C86803240 @default.
• W2891364583 hasConcept C8891405 @default.
• W2891364583 hasConceptScore W2891364583C126322002 @default.
• W2891364583 hasConceptScore W2891364583C137061746 @default.
• W2891364583 hasConceptScore W2891364583C167672396 @default.
• W2891364583 hasConceptScore W2891364583C170493617 @default.
• W2891364583 hasConceptScore W2891364583C202751555 @default.
• W2891364583 hasConceptScore W2891364583C203014093 @default.
• W2891364583 hasConceptScore W2891364583C2776090121 @default.
• W2891364583 hasConceptScore W2891364583C2778957590 @default.
• W2891364583 hasConceptScore W2891364583C2908885563 @default.
• W2891364583 hasConceptScore W2891364583C49802076 @default.
• W2891364583 hasConceptScore W2891364583C553184892 @default.
• W2891364583 hasConceptScore W2891364583C55493867 @default.
• W2891364583 hasConceptScore W2891364583C71924100 @default.
• W2891364583 hasConceptScore W2891364583C86803240 @default.
• W2891364583 hasConceptScore W2891364583C8891405 @default.
• W2891364583 hasFunder F4320309086 @default.
• W2891364583 hasIssue "10" @default.
• W2891364583 hasLocation W28913645831 @default.
• W2891364583 hasLocation W28913645832 @default.
• W2891364583 hasLocation W28913645833 @default.

• next